The dose-response data broke down as follows: 1mg dose: 8.7% average weight loss at 48 weeks 4mg dose: 15.2% average weight loss at 48 weeks 8mg dose: 21.1% average weight loss at 48 weeks 12mg dose: 24.2% average weight loss at 48 weeks Placebo: 2.1% average weight loss at 48 weeks The week-by-week progression told an equally compelling story
Triple agonist peptide targeting GLP-1, GIP, and glucagon receptors in metabolic research models
Format: Lyophilized powder, 24mg vial
For others, the knowledge that their struggle might assist others going forward validates painful hiatuses
So, whether there is a kind of medicine whose effects can cover as many targets as possible is a good question for liver disease therapy
This presentation was featured at the 2026 HOPA annual conference, March 25-27, in New Orleans, LA